Scope of the Study
Oral cancer is the uncontrollable growth of cells that invade and cause damage to surrounding tissue that develops in the tissues of the mouth or throat. This cancer belongs to a larger group of cancers called head and neck cancers. Over 49,000 cases of oral cancer are diagnosed each year in the United States, occurring most often in people over 40 years old. The risk factors for the development of oral cancer involve smoking, smokeless tobacco use, excessive consumption of alcohol, family history and others.
The market study is being classified and major geographies with country level break-up.
GE Healthcare (United States), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (United States), Siemens Healthineers (Germany), Hitachi Ltd (Japan), PeriRx, LLC (United States), Canon Medical Systems Corporation (Japan), Vigilant Biosciences, Inc. (United States), QIAGEN (Germany) and Koninklijke Philips NV (Netherlands) are some of the key players profiled in the study.
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Oral Cancer Diagnostics market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Oral Cancer Diagnostics market by Type, Application and Region.
On the basis of geography, the market of Oral Cancer Diagnostics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Prevalence of Oral Cancer
- Growing Healthcare Infrastructure in Developing Regions
- Increased Adoption of Effective Diagnostic Aids
- Increasing Awareness about Cancers and Its Treatments
- Increasing Number of Diagnostic Centres and Hospitals
- Lack of Healthcare Infrastructure in Under Developing Countries
- Side Effects of the Cancer Treatments
- Increased Government Funding for Research and Development Activities
- Rise in the Geriatric Population Worldwide
- Growth in the Healthcare Industry Worldwide
- Shortage of Skilled Professionals
- Stringent Government Rules and Regulations
In July 2020, Roche and Blueprint Medicines Corporation has announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialization outside the United States (US), excluding Greater China*. In the United States, Genentech, a member of the Roche Group, will obtain co-commercialization rights to trametinib, Blueprint Medicine’s investigational, once-daily oral precision therapy for the treatment of people with RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other types of thyroid cancer, as well as other solid tumors.
Key Target AudienceOral Cancer Diagnostics Manufacturers, Distributors, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase